Skip to main content

A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza┬┐) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Canc

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

AstraZeneca Pharmaceuticals, LP

Start Date

February 13, 2018

End Date

February 29, 2020
 

Administered By

Duke Cancer Institute

Awarded By

AstraZeneca Pharmaceuticals, LP

Start Date

February 13, 2018

End Date

February 29, 2020